Gradiant Bioconvergence
|
Year Established:
2022.04.01 |
|
|
Website:
gradiantbio.com |
|
|
Headquarters:
Seoul, Seoul, KR |
|
|
Company Type:
Mid-Sized Business (10-100M TTM Revenue) |
Gradiant Bioconvergence is the world’s first organoid company with the world’s largest cancer patient organoid bank, we carry out global businesses such as AI-based anticancer target discovery, biomarker screening, and disease modeling.
Our patient-derived organoids are established with genome analysis and drug reactivity. Our proprietary AI algorithm integrates multifaceted information to derive targets in an unprecedented and innovative way.
| Site | Badges | |
|---|---|---|
| Gradiant Bioconvergence 558, Songpa-daero, Songpa-gu, Seoul Seoul, Seoul, 05510 South Korea | ||
| Gradiant Bioconvergence 558, Songpa-daero, Songpa-gu, Seoul Seoul, Seoul, 05510 South Korea | ||
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.